Holen Sie sich die Stockscreener-App
18.12
0.93%
-0.17
Handel nachbörslich:
19.02
0.90
+4.97%
Schlusskurs vom Vortag:
$18.29
Offen:
$19.5
24-Stunden-Volumen:
169.79K
Relative Volume:
1.05
Marktkapitalisierung:
$649.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-20.07%
1M Leistung:
-24.06%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$18.00
$19.89
1-Wochen-Bereich:
$18.00
$22.87
52-Wochen-Spanne:
$18.00
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
1445A SOUTH 50TH STREET, RICHMOND
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BIOA | 18.12 | 649.58M | 0 | 0 | 0 | 0.00 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge Labs Reports Strong Q3 2024 Achievements - Yahoo Finance
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Reports Q3 Loss, Secures $334.5M Cash Runway Through 2029 After IPO | BIOA Stock News - StockTitan
BioArctic AB Sets Q3 2024 Earnings Call for November 14: Key Details Inside | BIOA Stock News - StockTitan
BioAge Labs, Inc. to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - Marketscreener.com
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - GlobeNewswire
BioAge Labs to Present at Jefferies London Healthcare Conference - GlobeNewswire
Citi sets BioAge Labs Buy stock rating on obesity drug potential - Investing.com
BioAge Labs initiated with an Overweight at Morgan Stanley - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship (NASDAQ:BIOA) - Seeking Alpha
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up - Investing.com Australia
Wall Street analysts initiate coverage of BioAge Labs By Investing.com - Investing.com Canada
BioAge Labs stock initiated at buy, key obesity trial data expected by 2025 – Jefferies - Investing.com Canada
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up By Investing.com - Investing.com South Africa
Prediction: These 2 Stocks Could Soar in 2025 - Yahoo Finance
Stocks To Watch: BioAge Labs Sees Relative Strength Rating Jump To 94 - Investor's Business Daily
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock - Yahoo! Voices
RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc - Yahoo Finance
BioAge Labs’ $238 Million Upsized Initial Public Offering - Global Legal Chronicle
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October - MSN
Bioage Labs director acquires $4.3m in common stock By Investing.com - Investing.com UK
Bioage Labs director acquires $4.3m in common stock - Investing.com
This IPO Biotech Stock Could Be the Next Eli Lilly - The Motley Fool
Cormorant Asset Management buys $8.1m in BioAge Labs stock - Investing.com India
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - The Manila Times
BioAge Labs Announces Closing of Initial Public Offering, - GlobeNewswire
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - ForexTV.com
Cormorant Asset Management buys $8.1m in BioAge Labs stock By Investing.com - Investing.com South Africa
Fenwick Represents BioAge Labs in $238 Million Upsized Initial Public Offering and Concurrent Private Placement - Fenwick & West LLP
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs director Enright buys $7.2 million in stock - Investing.com India
Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024 - Scrip
Wave financing, BioAge IPO help biotech end September strong - BioCentury
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock - Investing.com Australia
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock By Investing.com - Investing.com South Africa
BioAge Labs director Enright buys $7.2 million in stock By Investing.com - Investing.com Australia
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):